The Effect of Cardiac Rehabilitation on Oxidative DNA Damage and Inflammation in Patients With Coronary Artery Disease

NCT06867926 · tracked via the Priya Life Science Turkey tracker

Sponsor

TC Erciyes University

Phase

Not applicable

Started

2025-05-15

Last updated

2025-05-02

Condition(s) studied

Coronary Arterial Disease (CAD)

Investigational drug(s) / intervention(s)

Cardiac rehabilitation

Cardiac rehabilitation: Individuals diagnosed with coronary artery disease will engage in a programme of cardiac rehabilitation.

Study summary

The objective of this study was to determine the levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG), an indicator of oxidative stress, and to demonstrate oxidative DNA damage in cardiac rehabilitation treatment in patients with coronary artery disease. Additionally, proinflammatory cytokines TNFα, IL-1β, and IL-6 levels were measured to evaluate the significance of cardiac rehabilitation treatment in patients with coronary artery disease and to assess the correlation between cytokine levels and 8-OHdG levels.

Eligibility

Sex

ALL

Min age

18 Years

Max age

65 Years

Healthy volunteers

Accepted

Inclusion Criteria: Inclusion Criteria for Patient Volunteers 1. Patients aged 18-65 years with a diagnosis of coronary artery disease and no contraindications to cardiac rehabilitation and exercise testing 2. Patients who will undergo cardiopulmonary exercise testing before cardiac rehabilitation 3. Patients whose cognitive status is sufficient to complete the study and who can cooperate Inclusion Criteria for Healthy Volunteers 1. 18 years of age or older 2. Not having a chronic disease (such as uncontrolled diabetes mellitus, hypertension, heart and kidney failure) 3. Not taking regular medication Exclusion Criteria: Exclusion Criteria for Patient Volunteers 1. Having heart failure 2. Unstable Angina Pectoris 3. Complex ventricular arrhythmia 4. Having a pacemaker 5. Having orthopedic or neurological diseases that prevent exercise 6. Having kidney-liver disease 7. Exercise is contraindicated 8. History of inflammatory diseases 9. Having a history of cancer-immunologic disease Exclusion Criteria for Healthy Volunteers 1. Having a history of chronic diseases such as diabetes mellitus, hypertension, heart and kidney failure 2. Being on regular medication for the last 6 months 3. being under 18 years of age

Primary outcome measure(s)

8-OHdG — intervention group, two measurements- before cardiac rehabilitation (one day before the intervention) and two measurements will be taken after cardiac rehabilitation (at the end of the program)A single measurement will be performed on the healthy control
To measure 8-OHdG in serum samples, the investigators will analyze it using the ELISA kit following the kit procedure and measure it on an ELISA reader.
NADPH oxidase (NOX) — intervention group, two measurements- before cardiac rehabilitation (one day before the intervention) and two measurements will be taken after cardiac rehabilitation (at the end of the program)A single measurement will be performed on the healthy control
To measure NOX in serum samples, the investigators will analyze it using the ELISA kit following the kit procedure and measure it on an ELISA reader.
Total antioxidant capacity (TAC) — intervention group, two measurements- before cardiac rehabilitation (one day before the intervention) and two measurements will be taken after cardiac rehabilitation (at the end of the program)A single measurement will be performed on the healthy control
To measure TAC in serum samples, the investigators will analyze it using the ELISA kit following the kit procedure and measure it on an ELISA reader.
Total oxidant status (TOS) — intervention group, two measurements- before cardiac rehabilitation (one day before the intervention) and two measurements will be taken after cardiac rehabilitation (at the end of the program)A single measurement will be performed on the healthy control
To measure TOS in serum samples, the investigators will analyze it using the ELISA kit following the kit procedure and measure it on an ELISA reader.
Proinflammatory cytokines (TNFα, IL-1β and IL-6) — intervention group, two measurements- before cardiac rehabilitation (one day before the intervention) and two measurements will be taken after cardiac rehabilitation (at the end of the program)A single measurement will be performed on the healthy control
To measure TNFα, IL-1β and IL-6 in serum samples, the investigators will analyze it using the ELISA kit following the kit procedure and measure it on an ELISA reader.

Trial sites (1)

Facility	City	Region	Status
Erciyes University Faculty of Medicine	Kayseri	Turkey (Türkiye)	Recruiting

More TC Erciyes University trials in Turkey

Predicting Spinal Hypotension in Cesarean Section Recruiting

Diabetic Foot Education Enrolling by invitation

The Effect of Stress Ball Used During Intra Uterine Insemination on Pain, Anxiety, Comfort and Physiological Parameters Recruiting

The Effect of Wound Care Education Given to Patients on Wound Care Knowledge, Self-Care Self-Efficacy, and Quality of Recovery Active, not recruiting

Effect of Anesthesia Techniques on Quality of Recovery Scores in HOLEP Surgery Recruiting

Other trials for the same condition

Double Kissing-crush vs Controlled Balloon-crush Techniques For Complex Coronary Bfurcation Lesions Recruiting

Correlation of Euroscore-II, STS Risk Scoring Systems and Frailty Tests with Cardiac Histopathological Findings in Coronary Bypass Surgery Active, not recruiting

Impact of Preprocedural Stress Ball Use on Radial Artery Outcomes in Elective Coronary Angiography Starting soon

Erectile Dysfunction Progression After Percutaneous Coronary Angiography: Is Residual SYNTAX Score a Predictive Marker Active, not recruiting

Branching Scenario-Based Education in Coronary Artery Disease Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06867926 on ClinicalTrials.gov ↗ ← All trials in Turkey